Sofie L. M. Blokland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sofie L. M. Blokland has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Joel A. G. van Roon
Department of Rheumatology and Clinical Immunology, Utrecht University Medical Center, Utrecht University, Utrecht, Netherlands; Center of Translational Immunology, Utrecht University Medical Center, Utrecht University, Utrecht, Netherlands
2 shared publications Aike A. Kruize
Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
1 shared publication- Aike A. Kruize
University Medical Center Utrecht Department Rheumatology and Clinical Immunology Utrecht Netherlands
1 shared publication Andreas Kislat
Department of Dermatology, University of Düsseldorf, Düsseldorf, Germany
1 shared publicationArno N Concepcion
Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
1 shared publicationBernhard Homey
Department of Dermatology, University of Düsseldorf, Düsseldorf, Germany
1 shared publication
Latest Publications
- Open Access
- 16 November 2019
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 91 (3) , e12852
Decreased circulating CXCR3 + CCR9+T helper cells are associated with elevated levels of their ligands CXCL10 and CCL25 in the salivary gland of patients with Sjögren’s syndrome to facilitate their concerted migration
CCR9+ T helper (Th) cells can induce Sjögren‐like symptoms in mice and both CCR9+ Th‐cells and their ligand CCL25 are increased in the salivary glands of primary Sjögren's syndrome (pSS) patients. Increased circulating CCR9+ Th cells are present in pSS patients. CCR9+ Th cells are hyperresponsive to IL‐7, secrete high levels of IFN‐γ, IL‐21, IL‐17 and IL‐4 and potently stimulate B cells in both patients and healthy individuals. Our aim was to study co‐expression of chemokine receptors on CCR9+ Th cells and whether in pSS this might differentially affect CCR9+ Th cell frequencies. Frequencies of circulating CCR9+ and CCR9‐ Th‐cells co‐expressing CXCR3, CCR4, CCR6 and CCR10 were studied in pSS patients and healthy controls. CCL25, CXCL10, CCL17, CCL20 and CCL27 mRNA and protein expression of salivary gland tissue of pSS and non‐Sjögren's sicca (non‐SS) patients was assessed. Chemotaxis assays were performed to study migration induced by CXCL10 and CCL25. Higher expression of CXCR3, CCR4 and CCR6 but not CCR10 was observed on CCR9+ Th cells as compared to cells lacking CCR9. Decreased frequencies of circulating memory CCR9+CXCR3+ Th‐cells were found in pSS patients, which was most pronounced in the effector memory subset. Increased salivary gland CCL25 and CXCL10 expression significantly correlated and both ligands functioned synergistically based on in vitro induced chemotaxis. Decreased memory CXCR3+CCR9+ Th‐cells in blood of pSS patients may be due to a concerted action of overexpressed ligands at the site of inflammation in the salivary glands facilitating their preferential migration and positioning in the lymphocytic infiltrates.
- 16 November 2019
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 91 (3) , e12852
Open AccessDecreased circulating CXCR3 + CCR9+T helper cells are associated with elevated levels of their ligands CXCL10 and CCL25 in the salivary gland of patients with Sjögren’s syndrome to facilitate their concerted migration
CCR9+ T helper (Th) cells can induce Sjögren‐like symptoms in mice and both CCR9+ Th‐cells and their ligand CCL25 are increased in the salivary glands of primary Sjögren's syndrome (pSS) patients. Increased circulating CCR9+ Th cells are present in pSS patients. CCR9+ Th cells are hyperresponsive to IL‐7, secrete high levels of IFN‐γ, IL‐21, IL‐17 and IL‐4 and potently stimulate B cells in both patients and healthy individuals. Our aim was to study co‐expression of chemokine receptors on CCR9+ Th cells and whether in pSS this might differentially affect CCR9+ Th cell frequencies. Frequencies of circulating CCR9+ and CCR9‐ Th‐cells co‐expressing CXCR3, CCR4, CCR6 and CCR10 were studied in pSS patients and healthy controls. CCL25, CXCL10, CCL17, CCL20 and CCL27 mRNA and protein expression of salivary gland tissue of pSS and non‐Sjögren's sicca (non‐SS) patients was assessed. Chemotaxis assays were performed to study migration induced by CXCL10 and CCL25. Higher expression of CXCR3, CCR4 and CCR6 but not CCR10 was observed on CCR9+ Th cells as compared to cells lacking CCR9. Decreased frequencies of circulating memory CCR9+CXCR3+ Th‐cells were found in pSS patients, which was most pronounced in the effector memory subset. Increased salivary gland CCL25 and CXCL10 expression significantly correlated and both ligands functioned synergistically based on in vitro induced chemotaxis. Decreased memory CXCR3+CCR9+ Th‐cells in blood of pSS patients may be due to a concerted action of overexpressed ligands at the site of inflammation in the salivary glands facilitating their preferential migration and positioning in the lymphocytic infiltrates.
- Open Access
- 25 May 2019
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (12) , 2305-2314
Dysregulated miRNome of plasmacytoid dendritic cells from patients with Sjögren’s syndrome is associated with processes at the centre of their function
A considerable body of evidence supports a role for type-I IFN in the pathogenesis of primary SS (pSS). As plasmacytoid dendritic cells (pDCs) are a major source of type-I IFN, we investigated their molecular regulation by measuring expression of a large set of miRNAs. pDCs were isolated from peripheral blood of pSS patients (n = 30) and healthy controls (n = 16) divided into two independent cohorts (discovery and replication). Screening of 758 miRNAs was assessed by an OpenArray quantitative PCR-based technique; replication of a set of identified miRNAs was performed by custom array. Functional annotation of miRNA targets was performed using pathway enrichment. Novel targets of miR-29a and miR-29c were identified using a proteomic approach (stable isotope labelling with amino acids in cell culture). In the discovery cohort, 20 miRNAs were differentially expressed in pSS pDCs compared with healthy control pDCs. Of these, differential expression of 10 miRNAs was confirmed in the replication cohort. The dysregulated miRNAs were involved in phosphoinositide 3-kinase-Ak strain transforming and mammalian target of rapamycin signalling, as well as regulation of cell death. In addition, a set of novel protein targets of miR-29a and miR-29c were identified, including five targets that were regulated by both miRs. The dysregulated miRNome in pDCs of patients with pSS is associated with aberrant regulation of processes at the centre of pDC function, including type-I IFN production and cell death. As miR-29a and miR-29c are pro-apoptotic factors and several of the novel targets identified here are regulators of apoptosis, their downregulation in patients with pSS is associated with enhanced pDC survival.
- 25 May 2019
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (12) , 2305-2314
Open AccessDysregulated miRNome of plasmacytoid dendritic cells from patients with Sjögren’s syndrome is associated with processes at the centre of their function
A considerable body of evidence supports a role for type-I IFN in the pathogenesis of primary SS (pSS). As plasmacytoid dendritic cells (pDCs) are a major source of type-I IFN, we investigated their molecular regulation by measuring expression of a large set of miRNAs. pDCs were isolated from peripheral blood of pSS patients (n = 30) and healthy controls (n = 16) divided into two independent cohorts (discovery and replication). Screening of 758 miRNAs was assessed by an OpenArray quantitative PCR-based technique; replication of a set of identified miRNAs was performed by custom array. Functional annotation of miRNA targets was performed using pathway enrichment. Novel targets of miR-29a and miR-29c were identified using a proteomic approach (stable isotope labelling with amino acids in cell culture). In the discovery cohort, 20 miRNAs were differentially expressed in pSS pDCs compared with healthy control pDCs. Of these, differential expression of 10 miRNAs was confirmed in the replication cohort. The dysregulated miRNAs were involved in phosphoinositide 3-kinase-Ak strain transforming and mammalian target of rapamycin signalling, as well as regulation of cell death. In addition, a set of novel protein targets of miR-29a and miR-29c were identified, including five targets that were regulated by both miRs. The dysregulated miRNome in pDCs of patients with pSS is associated with aberrant regulation of processes at the centre of pDC function, including type-I IFN production and cell death. As miR-29a and miR-29c are pro-apoptotic factors and several of the novel targets identified here are regulators of apoptosis, their downregulation in patients with pSS is associated with enhanced pDC survival.